13F Holdings
中文EN

EW Edwards Lifesciences Corp

Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1099800 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.4%
TTM net income YoY-25.3%
TTM EPS YoY-23.7%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR-10.6%

Margins

Gross margin78.0%
Operating margin21.6%
Net margin15.3%
FCF margin21.3%
EBITDA margin24.2%

Returns

ROE9.7%
ROA7.5%
ROIC (approx.)12.1%
Asset turnover0.49x

Leverage & solvency

Liabilities / assets22.5%
Debt / equity0.06x
Current ratio4.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.68x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue4.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$6.07B$5.44B$5.01B$4.46B$5.23B
Cost of revenue$1.33B$1.12B$978.40M$723.70M$1.25B
Gross profit$4.73B$4.32B$4.03B$3.74B$3.98B
R&D expense$1.08B$1.05B$962.90M$843.60M$903.10M
SG&A expense$2.09B$1.79B$1.58B$1.36B$1.49B
Operating income$1.26B$1.38B$1.31B$1.50B$1.69B
Interest expense$20.40M$19.80M$17.60M$19.20M$18.40M
Pretax income$1.27B$1.55B$1.37B$1.52B$1.70B
Income tax$216.90M$152.10M$152.40M$195.50M$198.90M
Net income$1.07B$4.17B$1.40B$1.52B$1.50B
EBITDA$1.42B$1.53B$1.45B$1.64B$1.83B
EPS (basic)1.846.982.312.462.41
EPS (diluted)1.836.972.302.442.38
Weighted avg. shares (diluted)585.80M599.30M609.40M624.20M631.20M
Banking
Net interest income-$20.40M-$19.80M-$17.60M——
Balance sheet
Cash & equivalents$2.94B$3.06B$1.15B$772.60M$867.40M
Short-term investments$1.29B$930.70M$500.50M$446.30M$604.00M
Receivables$659.60M$609.10M$771.50M$643.00M$582.20M
Inventory$1.13B$1.09B$903.50M$875.50M$726.70M
Current assets$6.74B$6.29B$4.04B$3.10B$3.18B
PP&E, net$1.81B$1.69B$1.59B$1.63B$1.55B
Goodwill$1.77B$1.78B$1.15B$1.06B$1.17B
Intangibles$1.13B$1.18B$399.40M$285.20M$323.60M
Total assets$13.70B$13.06B$9.36B$8.29B$8.50B
Current liabilities$1.81B$1.51B$1.20B$1.02B$1.03B
Long-term debt$598.30M$597.70M$597.00M$596.30M$595.70M
Total debt$598.30M$597.70M$597.00M$596.30M$595.70M
Total liabilities$3.36B$2.99B$2.64B$2.49B$2.67B
Shareholders' equity$10.34B$10.00B$6.65B$5.81B$5.84B
Net debt-$2.34B-$2.46B-$551.00M-$176.30M-$271.70M
Shares outstanding580.70M588.60M601.10M608.30M624.10M
Cash flow statement
Operating cash flow$1.60B$542.30M$895.80M$1.22B$1.73B
Capital expenditure$260.20M$252.40M$253.00M$244.60M$325.80M
Free cash flow$1.33B$289.90M$642.80M$973.60M$1.41B
Investing cash flow-$712.90M$2.31B$173.80M$252.30M-$1.72B
Financing cash flow-$956.80M-$983.00M-$711.00M-$1.58B-$356.30M
Depreciation & amortization$156.60M$155.20M$144.90M$139.60M$134.80M
Stock-based compensation$158.10M$162.30M$139.40M$126.80M$109.30M
Share buybacks$893.40M$1.16B$879.60M$1.73B$512.80M

Free plan shows the latest 5 periods; Pro shows all 18 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.